Vice President and Head, Global Strategic Services, Rare Diseases @ From November 2014 to Present (1 year 2 months) Vice President and Head, Global Scientific Affairs, Rare Diseases @ • Represent Genzyme in discussions with government officials about lysosomal storage disorders, enzyme replacement therapy and newborn screening • Collaborate with expert physicians and patient advocacy groups to nominate Pompe disease and MPS I for inclusion in the newborn screening panel in the United States • Coordinate and manage lysosomal storage disorder R&D for diagnostic, newborn screening and biomarker monitoring technology development • Act as an internal expert to help Genzyme defend its Myozyme patents • Manage Genzyme’s relationship with the CDC • Develop comprehensive biomarker strategies for Gaucher disease, Fabry disease, Pompe disease and MPS I • Forge strong relationships with treating physicians, investigators and researchers. Initiate and manage appropriate educational and research programs • Contribute to the strategic development of life cycle management plans for Gaucher disease, Fabry disease, Pompe disease and MPS I • Host international meetings to discuss technology pros and cons and coordinate incorporation of suggestions into the project plans • Work with external collaborators to develop and publish novel methods • Established a Genzyme R&D lab to translate the published research methods into protocols for use in clinical labs and newborn screening labs From 2007 to 2014 (7 years) Senior Director of Science Strategy, Therapeutics R&D @ • Represent Genzyme in discussions with government officials about lysosomal storage disorders, enzyme replacement therapy and newborn screening • Collaborate with expert physicians and patient advocacy groups to nominate Pompe disease and MPS I for inclusion in the newborn screening panel in the United States • Coordinate and manage lysosomal storage disorder R&D for diagnostic, newborn screening and biomarker monitoring technology development • Act as an internal expert to help Genzyme defend its Myozyme patents • Manage Genzyme’s relationship with the CDC • Develop comprehensive biomarker strategies for Gaucher disease, Fabry disease, Pompe disease and MPS I • Forge strong relationships with treating physicians, investigators and researchers. Initiate and manage appropriate educational and research programs • Contribute to the strategic development of life cycle management plans for Gaucher disease, Fabry disease, Pompe disease and MPS I • Host international meetings to discuss technology pros and cons and coordinate incorporation of suggestions into the project plans • Work with external collaborators to develop and publish novel methods • Established a Genzyme R&D lab to translate the published research methods into protocols for use in clinical labs and newborn screening labs From 2004 to 2006 (2 years) Director of Science Strategy, Corporate R&D @ • Aligned the early stage R&D portfolio with business unit needs • Established a program management process for early stage R&D projects • Developed a common platform for early stage R&D program budgeting, reporting and review • Directed the development and integration of a custom corporate R&D project reporting database (gPoP) for all discovery and development R&D projects • Established a corporate-wide process for the review of unsolicited intellectual property and early stage R&D • Continued to manage the external collaborations to develop assays for lysosomal storage disorders From 2002 to 2004 (2 years) Associate Director of Science Strategy, Corporate R&D @ • Aligned the early stage R&D portfolio with business unit needs • Established a program management process for early stage R&D projects • Developed a common platform for early stage R&D program budgeting, reporting and review • Directed the development and integration of a custom corporate R&D project reporting database (gPoP) for all discovery and development R&D projects • Established a corporate-wide process for the review of unsolicited intellectual property and early stage R&D • Continued to manage the external collaborations to develop assays for lysosomal storage disorders From 2000 to 2002 (2 years) Market Development Manager, Therapeutics Global Marketing @ • Evaluated and made recommendations on the market potential of intellectual property • Provided market and competitor analysis • Designed and created education programs for MPS I, Pompe disease and Fabry disease • Acted as a scientific consultant to Program Management, Marketing and Business Development groups • Identified external collaborators and established multiple international scientific collaborations to develop technology useful for newborn screening for the lysosomal storage disorders, for disease-specific biomarkers, and to diagnose Pompe disease from using a sample derived from blood From 1998 to 2000 (2 years) Project Leader, Diagnostics Research Products R&D @ • Created and led the Strategic Product Acquisition Team that identified and evaluated new product line acquisitions and new technology opportunities • Pioneered the identification, license agreement negotiation, and implementation of a new product line of synthetic chemokines, and chemokine and chemokine receptor antibodies • Established and managed research collaborations to accelerate product development timelines • Provided scientific consultation and evaluated new technologies for the Business Development, Product Development and Marketing groups • Served as the R&D liaison with the Scientific Advisory Board • Established and managed a R&D group to develop a signal transduction product line and in-house bioassay and molecular biology capabilities From 1997 to 1998 (1 year) Principal Technical Marketing Specialist, Diagnostics Sales and Marketing @ • Provided technical support for a $15 MM product line of 300 research reagents to a worldwide sales force of 25, a network of 40 international distributors and all customers • Designed promotional literature, including catalogs, product inserts and manuscripts • Identified new product acquisition targets and initiated contact with academic and industry sources to begin license negotiation • Developed and presented multiple distinct comprehensive training programs and technical seminars for domestic and international use • Researched and devised a business plan for a signal transduction product line and received approval for implementation From 1995 to 1997 (2 years) Postdoctoral Research Fellow in Medicine, Hematology Division; Instructor, Harvard Medical School @ • Characterized the expression of bFGF and PDGF during erythroid differentiation • Utilized differential cDNA library screening to identify 20+ erythropoietin-regulated genes From January 1991 to November 1994 (3 years 11 months) Greater Boston Area

Doctor of Philosophy (Ph.D.), Molecular and Cellular Biology @ University of Kentucky From 1985 to 1990 BS, Biology @ Northern Kentucky University From 1981 to 1985 Greater Boston Executive Program in Business Management @ Massachusetts Institute of Technology - Sloan School of Management Joan Keutzer is skilled in: Biotechnology, Biopharmaceuticals, Clinical Development, Pharmaceutical Industry, Lifesciences, Oncology, Drug Discovery, Molecular Biology, Drug Development, Commercialization, Hematology, Medical Affairs, Clinical Trials, FDA, Regulatory Affairs